ReviewGene therapy2005
Angiogenic and antiangiogenic gene therapy.
Review in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- 3D Printed Bioconstructs: Regenerative Modulation for Genetic Expression.Stem cell reviews and reports · 2021Review
- Extracellular Matrix Mimicking Nanofibrous Scaffolds Modified With Mesenchymal Stem Cell-Derived Extracellular Vesicles for Improved Vascularization.Frontiers in bioengineering and biotechnology · 2020Article
- HIF-1α Dependent Wound Healing Angiogenesis In Vivo Can Be Controlled by Site-Specific Lentiviral Magnetic Targeting of SHP-2.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Multimodal Assessment of Mesenchymal Stem Cell Therapy for Diabetic Vascular Complications.Theranostics · 2017Article
- Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers.HIV/AIDS (Auckland, N.Z.) · 2017Review
- Translational suppression of HIF-1α by miconazole through the mTOR signaling pathway.Cellular oncology (Dordrecht, Netherlands) · 2014Article
- Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer.PloS one · 2012Article
- AAV2-mediated in vivo immune gene therapy of solid tumours.Genetic vaccines and therapy · 2010Article
- Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells.Oncology letters · 2010Article
- Ultrasonically targeted delivery into endothelial and smooth muscle cells in ex vivo arteries.Journal of controlled release : official journal of the Controlled Release Society · 2007Article
- Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.Drugs & aging · 2007Review
- Interactions of PPAR-alpha and adenosine receptors in hypoxia-induced angiogenesis.Vascular pharmacologyArticle
- Bacteria as vectors for gene therapy of cancer.Bioengineered bugsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy is thought to be a promising method for the treatment of various diseases. One gene therapy strategy involves the manipulations on a process of formation of new vessels, commonly defined as angiogenesis. Angiogenic and antiangiogenic gene therapy is a new therapeutic approach to the treatment of cardiovascular and cancer patients, respectively. So far, preclinical and clinical studies are successfully focused mainly on the treatment of coronary artery and peripheral artery diseases. Plasmid vectors are often used in preparations in angiogenic gene therapy trials. The naked plasmid DNA effectively transfects the skeletal muscles or heart and successfully expresses angiogenic genes that are the result of new vessel formation and the improvement of the clinical state of patients. The clinical preliminary data, although very encouraging, need to be well discussed and further study surely continued. It is really possible that further development of molecular biology methods and advances in gene delivery systems will cause therapeutic angiogenesis as well as antiangiogenic methods to become a supplemental or alternative option to the conventional methods of treatment of angiogenic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.